Belosalik oinment 30g (Salicylic acid) — Made in Croatia — Free Delivery

The preparation is not intended for use in ophthalmology. avoid contact with eyes, mucous membranes, wound surfaces and ulcers.

When applied to the skin of the face, the duration of the course of therapy should be limited to 5 days.

If skin irritation or hypersensitivity occurs during the use of the preparation, treatment should be discontinued. In the presence of infection, appropriate therapy should be prescribed.

If dandruff or keratinization disappears, continue treatment with only corticosteroids. Any side effects that occur with the use of systemic corticosteroids, including inhibition of the function of the adrenal cortex, can also occur with local application of GCS, especially in children.

Systemic absorption of corticosteroids or salicylic acid when applied topically will be higher if treatment is carried out on large surfaces of the body or when using occlusive dressings. Appropriate measures should be taken in such cases, especially when treating children.

Long-term preparation  therapy should be avoided in all patients, regardless of age.

With the development of excessive dryness or increased skin irritation, the preparation should be discontinued.

Topical corticosteroids can cause psoriasis for a variety of reasons, including recurrence of symptoms followed by the development of tolerance, the risk of pustular psoriasis and local systemic toxicity due to a decrease in the protective function of the skin. Patients with impaired liver function are most sensitive to systemic action. Careful observation of the patient is necessary. Topical corticosteroids can distort the clinical picture.

Relapse is possible if treatment is interrupted. An exacerbation of the infection may occur, and healing may also be slowed down.

The preparation should not be applied to mucous membranes or areas around the eyes due to the keratolytic action of salicylic acid.

Application of the preparation to areas with atrophied skin is contraindicated.

Use during pregnancy and lactation. Pregnancy. Since the safety of the use of topical corticosteroids in pregnant women has not been established, the preparation should not be used in the first trimeter of pregnancy. Prescribing corticosteroids later in pregnancy is possible if the expected benefit to the mother clearly outweighs the potential threat to the fetus. Preparations in this group are contraindicated for pregnant women in high doses and for a long time.

Breastfeeding period. At present, it is not clear whether corticosteroids, when applied topically as a result of systemic absorption, can penetrate into breast milk, therefore, when deciding whether to stop breastfeeding or discontinue the preparation, the need to prescribe the preparation should be taken into account.

Children. The preparation is used in children aged 2 years and older.

Application in children is possible only after consultation and under medical supervision. Consideration should be given to the greater absorption of the preparation in children due to the greater value of the ratio of the skin surface area to the child's body weight, which may manifest itself as an increase in systemic toxicity and inhibition of the hypothalamic-pituitary-adrenal system. The duration of treatment in children should be kept as short as possible. Children are more likely to have signs of suppression of the hypothalamic-pituitary-adrenal system and external corticosteroid effects under the influence of local corticosteroids than in adult patients. In children receiving treatment with topical corticosteroids, suppression of the hypothalamic-pituitary-adrenal system, Cushing's syndrome, linear growth retardation, insufficient body weight gain, and increased intracranial pressure may be observed. Manifestations of adrenal suppression in children: low blood plasma cortisol levels and lack of response to ACTH stimulation. Increased intracranial pressure is manifested by protrusion of the fontanelle, headache, bilateral edema of the optic nerve head.

Do not use under diapers.

The use of the preparation Belosalik is possible only when the expected benefit outweighs the potential risk of adverse reactions.

The ability to influence the reaction rate when driving or working with other mechanisms. Usually, the preparation does not affect the reaction rate when driving or operating other mechanisms.